JAKARTA, NETRALNEWS.COM - A new study published by the Journal of the National Cancer Institute shows that overall cancer-related deaths in both men and women have decreased.
From 2010 to 2014, the overall cancer deaths in men edged down by 1.8% per year, 1.4% per year in women, and 1.6% per year for children.
Researchers from several institutions, including the American Cancer Society and the National Cancer Institute, examined data from a cancer registry program based on population, and compiled by the North American Association of Central Cancer Registries (NAACCR) to look at deaths from cancer and the survival rate after diagnosis of cancer during different time periods from 1975 to 2014.
"Overall cancer death rate continues to go down in the United States, reflecting improvements in prevention, early detection, and treatment," the authors wrote, as quoted from ABC News.
They found an improvement in survival in a variety of the most common cancers between 2010 and 2014. In men, this improvement included a decrease in deaths from lung cancer by 3.5 percent per year, a decrease in prostate cancer deaths by 3.4 percent per year and a decrease in deaths from colorectal cancer in 2.5 percent per year.
In women, mortality rates decreased for 13 of the 18 most common cancers from 2010 to 2014. This included a decrease in deaths from breast cancer by 1.6 percent per year, deaths from lung cancer at 2.0 percent per year and deaths from colorectal cancer by 2.8 percent per year.
However, deaths from liver cancer increased by 2.6 percent per year for men and 3.0 percent per year for women. Deaths from brain cancer and pancreatic increase per year for men. As for women, deaths from cervical cancer have increased annually.
The authors noted that the decline in the death rate from cancer, possibly due to surveillance and prevention measures are better, while the new treatment has also helped increase life expectancy. They add that new treatments such as immunotherapy may lead to a significant improvement in the survival rate in the future.
"In an era of increasingly personalized cancer therapy, it is expected that dramatic improvements in the treatment and survival will be observed for other types of cancer as well," the authors write.
Despite these improvements, the authors noted that the medical community can not just think that this trend will continue as a "progress in reducing deaths and improving survival for some cancers is limited."
In addition, they showed that the cost of certain drugs can affect the results of the viability of this and that the medical community needs to pursue new treatments and ways for patients to access it in order to save more lives.
"Some of the new cancer drugs cost US $ 10,000 per month and is not covered even by the most insured patients because of the high price of the drug, which is about 20 percent of drug costs for insured patients," they wrote.
According to researchers, not only to develop an effective therapy and find drugs at affordable prices, but efforts to improve and implement measures for the prevention of rare cancer early proved to be effective in decreasing the death rate from this disease.